Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
R Russo, E Cozzani, G Gasparini… - Dermatologic …, 2020 - Wiley Online Library
R Russo, E Cozzani, G Gasparini, A Parodi
Dermatologic Therapy, 2020•Wiley Online LibraryBullous pemphigoid, mucous membrane pemphigoid, and pemphigus vulgaris are different
cutaneous autoimmune blistering diseases, with complex pathogenic mechanisms. In all of
them, a type‐2 response is thought to have a central role. Interleukin 4 and Interleukin 13
are crucial cytokines in type‐2 response. Treatment of these conditions is often challenging.
Dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to
human interleukin‐4 receptor IL‐4Rα, has the potential to inhibit both IL‐4 and IL‐13. We …
cutaneous autoimmune blistering diseases, with complex pathogenic mechanisms. In all of
them, a type‐2 response is thought to have a central role. Interleukin 4 and Interleukin 13
are crucial cytokines in type‐2 response. Treatment of these conditions is often challenging.
Dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to
human interleukin‐4 receptor IL‐4Rα, has the potential to inhibit both IL‐4 and IL‐13. We …
Abstract
Bullous pemphigoid, mucous membrane pemphigoid, and pemphigus vulgaris are different cutaneous autoimmune blistering diseases, with complex pathogenic mechanisms. In all of them, a type‐2 response is thought to have a central role. Interleukin 4 and Interleukin 13 are crucial cytokines in type‐2 response. Treatment of these conditions is often challenging. Dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin‐4 receptor IL‐4Rα, has the potential to inhibit both IL‐4 and IL‐13. We propose IL‐4Rα as a theoretical drug target for cutaneous autoimmune bullous diseases.
Wiley Online Library